Loading clinical trials...
Loading clinical trials...
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Parallel Group Phase III Study to Evaluate the Efficacy and Safety of STN1013800 Ophthalmic Solution in Chinese Patients With Acquired Blepharoptosis
Conditions
Interventions
STN1013800 ophthalmic solution
STN1013800 ophthalmic solution Liquid Base, without STN1013800
Locations
21
China
Anhui Provincial Hospital
Hefei, Anhui, China
The Second Hospital of Anhui Medical University
Hefei, Anhui, China
Beijing Chaoyang Hospital, Capital Medical University
Beijing, Beijing Municipality, China
Joint Shantou International Eye Center of Shantou University and the Chinese University of Hong Kong
Shantou, Guangdong, China
Affiliated Hospital of Guizhou Medical University
Guiyang, Guizhou, China
The first affiliated hospital of Zhengzhou University
Zhengzhou, He'nan, China
Start Date
October 22, 2024
Primary Completion Date
June 1, 2026
Completion Date
June 1, 2026
Last Updated
November 12, 2024
NCT03812016
NCT05945615
NCT05715346
NCT06292182
NCT01848041
NCT04807855
Lead Sponsor
Santen Pharmaceutical Co., Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions